^
    Apply
    Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ (NCT06846463)
    Phase 2
    Virginia Commonwealth University
    Not yet recruiting
    Last update posted :
    02/26/2025
    Initiation :
    06/30/2025
    Primary completion :
    07/31/2029
    Completion :
    07/31/2032
    BCL2 • NOTCH1 • MYD88 • CD79B • CD5
    |
    doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2029
    ALK • HLA-B • HLA-C
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT04240808)
    Phase 1
    University of Colorado, Denver
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/17/2020
    Primary completion :
    03/24/2023
    Completion :
    12/01/2025
    CD19
    |
    CD19 positive
    |
    UCD19 CAR T Cells
    Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03516617)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/10/2018
    Primary completion :
    03/15/2030
    Completion :
    03/15/2031
    CD20 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111-218) (NCT05068440)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/11/2021
    Primary completion :
    10/21/2025
    Completion :
    10/21/2025
    CD79B
    |
    CD79B mutation • CD79B mutation
    |
    Brukinsa (zanubrutinib)
    Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/02/2021
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    TP53 • IGH
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab)
    Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCI-2020-09704) (NCT04640779)
    Phase 1
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2021
    Primary completion :
    08/15/2026
    Completion :
    08/15/2027
    XPO1
    |
    Xpovio (selinexor)
    TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/19/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    PD-L1 • ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive
    |
    Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
    QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790)
    Phase 1/2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/24/2025
    Initiation :
    12/01/2017
    Primary completion :
    01/01/2019
    Completion :
    12/23/2021
    CD20
    |
    CD20 positive
    |
    Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous
    Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL (NCT01496976)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/30/2012
    Primary completion :
    10/06/2021
    Completion :
    03/25/2025
    CD20 • CD5
    |
    lenalidomide • Arzerra (ofatumumab)
    Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health (AMPLIFY) (NCT04000880)
    Phase N/A
    University of Alabama at Birmingham
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/04/2020
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    IL6 • TNFA • CRP
    Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCI#10057) (NCT02978625)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/27/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PD-L1 • ALK • NECTIN1
    |
    ALK positive • ALK negative
    |
    Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (BP41072) (NCT04077723)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/13/2019
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    CD20 • CD19
    |
    CD20 expression • CD19 expression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)
    QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (NCT04052061)
    Phase 1
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/16/2019
    Primary completion :
    09/18/2021
    Completion :
    08/19/2022
    CD19
    |
    CD19 expression
    |
    CD19.t-haNK
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (NCT03223610)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/09/2018
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone
    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (19-C-0116) (NCT04002947)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2026
    Completion :
    03/31/2030
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (NCT02160015)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2014
    Primary completion :
    03/27/2017
    Completion :
    08/13/2025
    CD20 • CD4 • CD5 • FCER2
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)
    Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (NCT06834373)
    Phase 2
    Mayo Clinic
    Not yet recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/03/2025
    Primary completion :
    03/03/2027
    Completion :
    03/03/2027
    BCL2
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers (NCT00788684)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    07/21/2009
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • navitoclax (ABT 263)
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6 • CD4
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (NCT00740805)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/18/2008
    Primary completion :
    09/03/2021
    Completion :
    10/22/2025
    HER-2 • ER • PGR • BRCA1 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous
    Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (P30CA033572) (NCT03113500)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/25/2017
    Primary completion :
    07/16/2021
    Completion :
    08/12/2025
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
    A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL (ONO-7018-01) (NCT05515406)
    Phase 1
    Ono Pharmaceutical Co. Ltd
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/13/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    MALT1
    |
    ONO-7018
    Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma (A051902) (NCT04803201)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/08/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous
    CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (PRO00037171) (NCT04186520)
    Phase 1/2
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/18/2020
    Primary completion :
    06/30/2026
    Completion :
    06/01/2028
    BCL2
    |
    CAR-20/19-T Cells
    Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (NCT04833114)
    Phase 3
    GWT-TUD GmbH
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/30/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (GO29781) (NCT02500407)
    Phase 1/2
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    09/15/2015
    Primary completion :
    05/21/2024
    Completion :
    09/30/2025
    CD20
    |
    Tecentriq (atezolizumab) • Lunsumio (mosunetuzumab-axgb)
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    11/05/2015
    Primary completion :
    01/25/2018
    Completion :
    07/01/2025
    HLA-DRB1
    |
    Triplex (CMV-MVA vaccine)
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04665765)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/18/2021
    Primary completion :
    07/26/2022
    Completion :
    07/08/2025
    CD20
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (SKYGLO) (NCT06047080)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/18/2023
    Primary completion :
    06/01/2026
    Completion :
    02/28/2029
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    Study of Oral MRT-2359 in Selected Cancer Patients (MRT-2359-001) (NCT05546268)
    Phase 1/2
    Monte Rosa Therapeutics, Inc
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/12/2022
    Primary completion :
    05/01/2026
    Completion :
    11/01/2027
    MYC • MYCN
    |
    MYCN amplification • MYC expression
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359
    Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma (C402-001) (NCT06830031)
    Phase 1
    Shanghai Exuma Biotechnology Ltd.
    Not yet recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/24/2025
    Primary completion :
    03/09/2026
    Completion :
    05/11/2026
    BCL2
    A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) (NCT05171647)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    04/25/2022
    Primary completion :
    05/30/2025
    Completion :
    02/28/2027
    CD20 • CD4
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) (NCT03570892)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    05/07/2019
    Primary completion :
    05/06/2021
    Completion :
    02/14/2026
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
    Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL (PBCAR0191-01) (NCT03666000)
    Phase 1
    Imugene Limited
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/11/2019
    Primary completion :
    06/01/2025
    Completion :
    06/01/2027
    CRP
    |
    cyclophosphamide • bendamustine • fludarabine IV • azercabtagene zapreleucel (PBCAR0191) • cyclophosphamide intravenous
    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (A051701) (NCT03984448)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/22/2019
    Primary completion :
    04/01/2028
    Completion :
    04/01/2028
    MYC • BCL2 • BCL6
    |
    BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous